Parkinson's treatment could be more effective, student finds

January 4, 2018, Binghamton University

A Binghamton University senior and her colleagues recently uncovered evidence that the current treatment for Parkinson's disease may not be as effective as it could be.

Lakshmi Hareendran was part of a research team investigating drug treatment for Parkinson's, a neurodegenerative disorder caused by a loss of the chemical dopamine.

The dopamine circuit involved in motor movements consists of two receptors in the brain, the D1 and the D2 receptors. The current treatment for Parkinson's is the drug L-DOPA, which acts on both of these receptors to release and replenish dopamine in the brain.

Hareendran and her colleagues in the Freshman Research Immersion program (FRI) at Binghamton provided evidence that stimulating the D2 receptor produces cognitive deficits, illustrating that L-DOPA may not be the best treatment for Parkinson's.

The researchers treated rodents with L-DOPA and drugs that target either the D1 or the D2 receptors and then observed the effects on their ability to complete a behavioral task.

Stimulating the D2 receptor caused attention deficits on the behavioral tasks in both Parkinson's and control models. Stimulating the D1 receptor produced no such effects.

"Parkinson's disease is one of the most common neurodegenerative diseases in the world," Hareendran says. "Knowing that the current treatment isn't as effective as it could be is important."

Hareendran, 21, has wanted to be a doctor since she was growing up on Long Island, influenced by several doctors in her family. Even then, she was interested in neuroscience.

"I had an uncle who was a brain surgeon," Hareendran says. "As a kid, just thinking about him being able to understand something as complex as the human brain really inspired me to go down that path."

Hareendran wants to work with Doctors Without Borders someday. An experience with MEDLIFE, an organization that provides medical care to impoverished areas, helped to solidify her goal. Hareendran traveled with the group to Peru and Ecuador to help set up medical clinics.

"My parents are refugees from Sri Lanka," Hareendran says. "There was a genocide happening there for a while, so specifically with Doctors Without Borders I want to go and give back there."

Hareendran is also president of the Indian International Student Union and was a peer mentor for FRI after she finished the program.

Corinne Kiessling, research educator for the FRI neuroscience stream, emphasized Hareendran's dedication.

"She was one of those students that puts extra hours in, came in early, stayed late," Kiessling says. "As a peer mentor, she was very open and receptive, and she challenged students to find answers. She's a natural leader."

Explore further: New drug may treat and limit progression of Parkinson's disease

More information: urjp.psych.ucla.edu/wp-content … reads-with-Cover.pdf

Related Stories

New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

Parkinson's disease drug shows anticancer effects

September 28, 2017
Research shows the Parkinson's disease drug carbidopa displays significant anticancer effects in both human cell lines and mice when given at normal patient dosage levels.

New technique can provide better cell transplants against Parkinson's disease

May 5, 2016
Researchers at Lund University in Sweden have used a completely new preclinical technique and analysis of tissue from patients to show exactly what happens when certain patients with Parkinson's disease are restored as a ...

New avenue to treat diabetes-related vision problems

January 22, 2014
Dopamine-restoring drugs already used to treat Parkinson's disease may also be beneficial for the treatment of diabetic retinopathy, a leading cause of blindness in adults, researchers have discovered.

Intracellular dopamine receptor function may offer hope to schizophrenia patients

December 9, 2016
Dopamine is a chemical in the brain that plays an important role in controlling movement, emotion and cognition. Dopamine dysfunction is believed to be one of the causes of disorders like Schizophrenia, Tourette's syndrome, ...

Recommended for you

Two compounds in coffee may team up to fight Parkinson's

December 10, 2018
Rutgers scientists have found a compound in coffee that may team up with caffeine to fight Parkinson's disease and Lewy body dementia—two progressive and currently incurable diseases associated with brain degeneration.

New Parkinson's disease drug target revealed through study of fatty acids

December 4, 2018
The human brain is rich in lipids. Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the ...

A toxin that travels from stomach to brain may trigger Parkinsonism

December 4, 2018
Combining low doses of a toxic herbicide with sugar-binding proteins called lectins may trigger Parkinsonism—symptoms typical of Parkinson's disease like body tremors and slowing of body motions—after the toxin travels ...

Experimental cancer drug shows promise for Parkinson's

December 3, 2018
The study, funded by Parkinson's UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson's. This happens when the drug interacts with a protein inside brain ...

Parkinson's therapy creates new brain circuits for motor function, study finds

November 28, 2018
Scientists have uncovered that an emerging gene therapy for Parkinson's disease creates new circuits in the brain associated with improved motor movement. These findings, published today in Science Translational Medicine ...

The puzzle of a mutated gene lurking behind many Parkinson's cases

November 15, 2018
Genetic mutations affecting a single gene play an outsized role in Parkinson's disease. The mutations are generally responsible for the mass die-off of a set of dopamine-secreting, or dopaminergic, nerve cells in the brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.